Why Doctor Care Anywhere (ASX:DOC) is soaring 12% today

The telehealth company has announced a new series of remote appointment options.

The Doctor Care Anywhere Group PLC (ASX: DOC) share price has leapt today after the company announced a new offering to patients.

The telehealth company has introduced a new operating model, moving from the single option of a 20-minute virtual consultation with a doctor to multiple options for treatment advice. 

At time of writing, the Doctor Care Anywhere share price is up 12%, trading at 46.5 cents apiece. 

An older woman clasps her hands with joy, smiling at the news on her computer as she sits at her kitchen bench..

Image source: Getty Images

New Telehealth options in place for patients

With COVID-19 spearheading the uptake of remote appointments, the Federal Health Department this week announced a $308.6 million injection into the primary care health system. This includes a $106 million portion for permanent Telehealth for Australians.

The announcement times well for Doctor Care Anywhere, with its new model including options such as shorter appointments, meeting with a nurse, or completing a QuickConsult survey to be reviewed and returned with written advice or a prescription. 

The company said this model would assist in "the challenge of clinical workforce shortages and ever-increasing healthcare demand". 

In addition, the telehealth company announced that its current agreement held with AXA Health would now vary to allow nurses to "make decisions in the assessment, diagnosis, and treatment of patients and to prescribe medication".

Doctor Care Anywhere share price snapshot

The Doctor Care Anywhere share price has fallen 61.67% since the company listed on the ASX in December last year. The company saw a high volume of trading on Monday following the government's healthcare investment.

Based on the current share price, the telehealth company has a market capitalisation of around $89 million.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Doctor Care Anywhere Group PLC. The Motley Fool Australia has recommended Doctor Care Anywhere Group PLC. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »